GR3007031T3 - - Google Patents

Info

Publication number
GR3007031T3
GR3007031T3 GR920402953T GR920402953T GR3007031T3 GR 3007031 T3 GR3007031 T3 GR 3007031T3 GR 920402953 T GR920402953 T GR 920402953T GR 920402953 T GR920402953 T GR 920402953T GR 3007031 T3 GR3007031 T3 GR 3007031T3
Authority
GR
Greece
Prior art keywords
hcmv
protein
human
immunogenic
vaccines
Prior art date
Application number
GR920402953T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3007031T3 publication Critical patent/GR3007031T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GR920402953T 1986-06-12 1993-02-11 GR3007031T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3619718 1986-06-12

Publications (1)

Publication Number Publication Date
GR3007031T3 true GR3007031T3 (enExample) 1993-07-30

Family

ID=6302829

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402953T GR3007031T3 (enExample) 1986-06-12 1993-02-11

Country Status (8)

Country Link
US (2) US5728578A (enExample)
EP (1) EP0252531B1 (enExample)
JP (2) JP2732840B2 (enExample)
AT (1) ATE82985T1 (enExample)
AU (1) AU605155B2 (enExample)
DE (1) DE3782867D1 (enExample)
ES (1) ES2044881T3 (enExample)
GR (1) GR3007031T3 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132533T1 (de) * 1988-02-24 1996-01-15 Behringwerke Ag Strukturelles phosphoprotein (pp28) des menschlichen cytomegalovirus (hcmv), seine herstellung und verwendung
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
DK0389286T3 (da) * 1989-03-24 1996-11-18 Wistar Inst Rekombinant-cytomegalovirus-vaccine
US5552143A (en) * 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9014652D0 (en) * 1990-07-02 1990-08-22 Wellcome Found Antigen
DE4128684A1 (de) * 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
US5744298A (en) * 1991-08-29 1998-04-28 Behringwerke Aktiengesellschaft DNA sequences which encode immunoreactive HCMV-specific peptides
AU2809897A (en) * 1996-04-23 1997-11-12 Wistar Institute Of Anatomy And Biology, The Novel human cytomegalovirus dna constructs and uses therefor
DE60109633T2 (de) * 2000-10-20 2006-01-19 City Of Hope, Duarte Immunreaktive peptidische ctl-epitope aus dem menschlichen cytomegalovirus pp150
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
BR112012015523A2 (pt) 2009-12-23 2017-04-18 4-Antibody Ag membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv.
CN104569387B (zh) * 2015-01-13 2017-06-16 必欧瀚生物技术（合肥）有限公司 一种ELISA检测人血清HCMV pp150 IgM抗体试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4762780A (en) * 1984-04-17 1988-08-09 The Regents Of The University Of California Method and composition for screening and diagnosing "HCMV"
GB8404368D0 (en) * 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US4743562A (en) * 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4808518A (en) * 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay

Also Published As

Publication number Publication date
JPS62296893A (ja) 1987-12-24
US5846733A (en) 1998-12-08
AU605155B2 (en) 1991-01-10
DE3782867D1 (en) 1993-01-14
ATE82985T1 (de) 1992-12-15
AU7412887A (en) 1987-12-17
EP0252531B1 (de) 1992-12-02
ES2044881T3 (es) 1994-01-16
JP3272641B2 (ja) 2002-04-08
JP2732840B2 (ja) 1998-03-30
EP0252531A1 (de) 1988-01-13
JPH10113190A (ja) 1998-05-06
US5728578A (en) 1998-03-17

Similar Documents

Publication Publication Date Title
AU6733487A (en) Mammalian interleukin-4
GR3007031T3 (enExample)
FI101381B1 (fi) Nukleotidisekvenssi ja menetelmä polypeptidin HSA(1-387) tuottamiseksi
ATE43635T1 (de) Verfahren zur herstellung von interferon und expressionsvektoren dafuer.
PH25312A (en) Preparation of functional human urokinase proteins
ZA951008B (en) N-terminally chemically modificed protein compositions and method
DE59010915D1 (de) Toxoplasma gondii-Antigene, ihre Herstellung und ihre Verwendung
GR860914B (en) Expression of immunologically reactive viral proteins
AU6941287A (en) Vaccines for human respiratory virus
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
DE3884680D1 (de) Äusseres Membranprotein F von Pseudomonas aeruginosa.
AU7440087A (en) Process for isolating and purifying p. falciparum cs protein vaccine expressed in recombinant e. coli
IE871639L (en) Varicella-zoster virus.
AU1216988A (en) Immunogenic fusion proteins which contain Epstein-Barr virus protein
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
IL86699A0 (en) Cell system for expression of recombinant protein without production of virus
AU2713488A (en) Process for manufacturing antigens, vaccines and sera to combat bacterial or viral diseases and composition for implementing said process
IE871932L (en) Method for the preparation of proteins with factor viii¹activity by microbial host cells, expression vectors, host¹cells, antibodies